206 related articles for article (PubMed ID: 33437353)
1. Promising long noncoding RNA DLX6-AS1 in malignant tumors.
Xue C; Lv L; Jiang J; Li L
Am J Transl Res; 2020; 12(12):7682-7692. PubMed ID: 33437353
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA DLX6-AS1 promotes liver cancer by increasing the expression of WEE1 via targeting miR-424-5p.
Li D; Tang X; Li M; Zheng Y
J Cell Biochem; 2019 Aug; 120(8):12290-12299. PubMed ID: 30805988
[TBL] [Abstract][Full Text] [Related]
3. DLX6-AS1 is a potential biomarker and therapeutic target in cancer initiation and progression.
Zheng Q; Gu X; Yang Q; Chu Q; Dai Y; Chen Z
Clin Chim Acta; 2021 Jun; 517():1-8. PubMed ID: 33607068
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between long non-coding RNA DLX6-AS1, microRNAs and signaling pathways: A pivotal molecular mechanism in human cancers.
Alizadeh A; Jebelli A; Baradaran B; Amini M; Oroojalian F; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Gene; 2021 Feb; 769():145224. PubMed ID: 33059027
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA DLX6-AS1 silencing inhibits malignant phenotypes of gastric cancer cells.
Fu X; Tian Y; Kuang W; Wen S; Guo W
Exp Ther Med; 2019 Jun; 17(6):4715-4722. PubMed ID: 31105791
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway.
Zhao J; Liu HR
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3243-3252. PubMed ID: 31081076
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA DLX6-AS1 functions as a competing endogenous RNA for miR-577 to promote malignant development of colorectal cancer.
Zhou FR; Pan ZP; Shen F; Huang LQ; Cui JH; Cai K; Guo XL
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3742-3748. PubMed ID: 31115000
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA DLX6-AS1 promotes tumorigenesis by modulating miR-497-5p/FZD4/FZD6/Wnt/β-catenin pathway in pancreatic cancer.
Yang J; Ye Z; Mei D; Gu H; Zhang J
Cancer Manag Res; 2019; 11():4209-4221. PubMed ID: 31118816
[TBL] [Abstract][Full Text] [Related]
9. The up-regulated lncRNA DLX6-AS1 in colorectal cancer promotes cell proliferation, invasion and migration via modulating PI3K/AKT/mTOR pathway.
Zhang JJ; Xu WR; Chen B; Wang YY; Yang N; Wang LJ; Zhang YL
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8321-8331. PubMed ID: 31646562
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA DLX6-AS1 promotes neuroblastoma progression by regulating miR-107/BDNF pathway.
Zhang HY; Xing MQ; Guo J; Zhao JC; Chen X; Jiang Z; Zhang H; Dong Q
Cancer Cell Int; 2019; 19():313. PubMed ID: 31787850
[TBL] [Abstract][Full Text] [Related]
11. DLX6 Antisense RNA 1 Modulates Glucose Metabolism and Cell Growth in Gastric Cancer by Targeting microRNA-4290.
Qian Y; Song W; Wu X; Hou G; Wang H; Hang X; Xia T
Dig Dis Sci; 2021 Feb; 66(2):460-473. PubMed ID: 32239379
[TBL] [Abstract][Full Text] [Related]
12. LncRNA DLX6-AS1 promotes tumor proliferation and metastasis in osteosarcoma through modulating miR-641/HOXA9 signaling pathway.
Zhang N; Meng X; Mei L; Zhao C; Chen W
J Cell Biochem; 2019 Jul; 120(7):11478-11489. PubMed ID: 30838699
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA DLX6-AS1 mediates proliferation, invasion and apoptosis of endometrial cancer cells by recruiting p300/E2F1 in DLX6 promoter region.
Zhao H; Xu Q
J Cell Mol Med; 2020 Nov; 24(21):12572-12584. PubMed ID: 32951317
[TBL] [Abstract][Full Text] [Related]
14. LncRNA DLX6-AS1 promoted cancer cell proliferation and invasion by attenuating the endogenous function of miR-181b in pancreatic cancer.
An Y; Chen XM; Yang Y; Mo F; Jiang Y; Sun DL; Cai HH
Cancer Cell Int; 2018; 18():143. PubMed ID: 30250401
[TBL] [Abstract][Full Text] [Related]
15. The lncRNA DLX6-AS1 promoted cell proliferation, invasion, migration and epithelial-to-mesenchymal transition in bladder cancer via modulating Wnt/β-catenin signaling pathway.
Guo J; Chen Z; Jiang H; Yu Z; Peng J; Xie J; Li Z; Wu W; Cheng Z; Xiao K
Cancer Cell Int; 2019; 19():312. PubMed ID: 31787849
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer.
Huang Y; Ni R; Wang J; Liu Y
Biomed Pharmacother; 2019 Jan; 109():1851-1859. PubMed ID: 30551440
[TBL] [Abstract][Full Text] [Related]
17. DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA.
Hu C; Liu K; Wang B; Xu W; Lin Y; Yuan C
Curr Pharm Des; 2021; 27(9):1211-1218. PubMed ID: 33121401
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA DLX6-AS1 promotes breast cancer progression via miR-505-3p/RUNX2 axis.
Zhao P; Guan H; Dai Z; Ma Y; Zhao Y; Liu D
Eur J Pharmacol; 2019 Dec; 865():172778. PubMed ID: 31705901
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of long noncoding RNA DLX6-AS1 promotes cell growth and metastasis in esophageal squamous cell carcinoma via targeting miR-577.
Wu SB; Wang HQ
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1195-1201. PubMed ID: 32096208
[TBL] [Abstract][Full Text] [Related]
20. Serum Exosomal lncRNA DLX6-AS1 Is a Promising Biomarker for Prognosis Prediction of Cervical Cancer.
Ding XZ; Zhang SQ; Deng XL; Qiang JH
Technol Cancer Res Treat; 2021; 20():1533033821990060. PubMed ID: 33550924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
